open access

Vol 14, No 5 (2019)
Heart failure
Published online: 2019-10-31
Get Citation

Sacubitril/valsartan predischarge for patient in acute heart failure with reduced ejection fraction of left ventricle — the earlier, the better

Małgorzata Lelonek
DOI: 10.5603/FC.2019.0103
·
Folia Cardiologica 2019;14(5):510-515.

open access

Vol 14, No 5 (2019)
Heart failure
Published online: 2019-10-31

Abstract

Based on results of trials TRANSITION and PIONIEER-HF the Heart Failure Association of the European Society of Cardiology reported an expert consensus 2019 that the initiation of sacubitril/valsartan rather than an angiotensin-converting enzyme (ACE) inhibitors or an angiotensin II type 1 receptor blocker may be considered for patients hospitalized with new-onset heart failure with reduced ejection fraction (HFrEF) or decompensated chronic HFrEF to reduce the short-term risk of adverse events and to simplify management by avoiding the need to titrate ACE inhibitors first and then switch to angiotensin receptor neprilysin inhibitor (ARNI). The paper described the new data from the two trials TRANSITION and PIONIEER-HF.

Abstract

Based on results of trials TRANSITION and PIONIEER-HF the Heart Failure Association of the European Society of Cardiology reported an expert consensus 2019 that the initiation of sacubitril/valsartan rather than an angiotensin-converting enzyme (ACE) inhibitors or an angiotensin II type 1 receptor blocker may be considered for patients hospitalized with new-onset heart failure with reduced ejection fraction (HFrEF) or decompensated chronic HFrEF to reduce the short-term risk of adverse events and to simplify management by avoiding the need to titrate ACE inhibitors first and then switch to angiotensin receptor neprilysin inhibitor (ARNI). The paper described the new data from the two trials TRANSITION and PIONIEER-HF.

Get Citation

Keywords

sacubitril/valsartan, acute heart failure, HFrEF, predischarge

About this article
Title

Sacubitril/valsartan predischarge for patient in acute heart failure with reduced ejection fraction of left ventricle — the earlier, the better

Journal

Folia Cardiologica

Issue

Vol 14, No 5 (2019)

Pages

510-515

Published online

2019-10-31

DOI

10.5603/FC.2019.0103

Bibliographic record

Folia Cardiologica 2019;14(5):510-515.

Keywords

sacubitril/valsartan
acute heart failure
HFrEF
predischarge

Authors

Małgorzata Lelonek

References (6)
  1. Wachter R, Senni M, Belohlavek J, et al. TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019; 21(8): 998–1007.
  2. Pascual-Figal D, Senni M, Belohlavek J, et al. Short-term effect on cardiac biomarkers of initiation of sacubitril/valsartan in hospitalized patients with heart failure and reduced ejection fraction: results of the TRANSITION study. Poster [Su2183] presented at AHA Congress 2018, Chicago, USA.
  3. Velazquez EJ, Morrow DA, DeVore AD, et al. PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019; 380(6): 539–548.
  4. Matyjas K, Lelonek M. Pacjent z niewydolnością serca w okresie vulnerable phase. Folia Cardiol. 2018; 13(1): 71–78.
  5. Greene SJ, Fonarow GC, Vaduganathan M, et al. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol. 2015; 12(4): 220–229.
  6. Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 [Epub ahead of print].

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl